In January 2013 Pharmacosmos broke ground for a significant expansion of its production site in Holbaek.
An expansion of Pharmacosmos' production facilities in Holbaek will reinforce the company's position as one of the world's leading suppliers of dextrans, dextran derivatives and carbohydrate polymers.
The products are used as carrier substances in wide variety of drugs and have recently been shown to be suitable for use in connection with the freezing of the stem cells.
"We start work in January and expect that the new plant is ready for use by the end of 2013," said Lars Christensen, MD and CEO at Pharmacosmos.
The total investment amounts to 9 million dollars and is part of a focused effort to use the company's expertise in carbohydrates to further develop its dextran business.
The new top-class production plant is destined for production of DEAE dextran, dextran derivatives and other carbohydrate polymers based on the present clinical grade Pharmacosmos product portfolio.
"Today, we have a strong base with both human and veterinary products as well as our clinical and technical dextrans. However, we can see that the market for dextrans, its derivatives and carbohydrates is growing and thus is extremely interesting, "said Lars Christensen.
*Note that the picture above is computer animated
Pay by Visa, MasterCard or bank transfer
Download certificates and documentation.
Pharmacosmos is the only dextran manufacturer holding certificates from the US FDA and European Directorate for the Quality of Medicines (EDQM)
Pharmacosmos delivers a unique dextran quality through a production technology that completely avoids the use of organic solvents and a quality system that meets the strictest cGMP standards for human medicines
Pharmacosmos sells and ships directly to clients everywhere in the World. We deliver Pharmaceutical Quality Dextran of the highest standards, including those of the European Pharmacopoeia (EP), the United States Pharmacopoeia (USP), and the Japanese Pharmacopoeia (JP).